منابع مشابه
New efforts develop therapeutic antibodies
Since the development of monoclonal antibodies twenty-five years ago, researchers and biotech companies have been looking to develop therapeutic uses for them. Michael Gross looks at some of the latest efforts.
متن کاملInforming Efforts to Develop Nitroreductase for Amine Production.
Nitroreductases (NRs) hold promise for converting nitroaromatics to aromatic amines. Nitroaromatic reduction rate increases with Hammett substituent constant for NRs from two different subgroups, confirming substrate identity as a key determinant of reactivity. Amine yields were low, but compounds yielding amines tend to have a large π system and electron withdrawing substituents. Therefore, we...
متن کاملBiased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors
BET bromodomain inhibition has contributed new insights into gene regulation and emerged as a promising therapeutic strategy in cancer. Structural analogy of early methyl-triazolo BET inhibitors has prompted a need for structurally dissimilar ligands as probes of bromodomain function. Using fluorous-tagged multicomponent reactions, we developed a focused chemical library of bromodomain inhibito...
متن کاملNot just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers
Mutations in Kirsten rat-sarcoma (KRAS) are well appreciated to be major drivers of human cancers through dysregulation of multiple growth and survival pathways. Similar to many other non-kinase oncogenes and tumor suppressors, efforts to directly target KRAS pharmaceutically have not yet materialized. As a result, there is broad interest in an alternative approach to develop therapies that ind...
متن کاملQuantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
KRAS has proven difficult to target pharmacologically. Two strategies have recently been described for covalently targeting the most common KRAS mutant in lung cancer, KRAS G12C. Previously, we developed a computational model of the processes that regulate Ras activation. Here, we use this model to investigate KRAS G12C covalent inhibitors. We updated the model to include Ras protein turnover, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cold Spring Harbor Perspectives in Medicine
سال: 2017
ISSN: 2157-1422
DOI: 10.1101/cshperspect.a031864